Search - tctmd.com

Displaying 1 - 12 of 12

Sort: Relevancy | Date

News Daily News

Blood Pressures Measured at Home Better Predict CAD Events Than Do Clinic Readings

Todd Neale

March 29, 2016

News Daily News

Comparative Analysis Suggests ACE Inhibitors Equivalent to ARBs in Patients Without Heart Failure

Michael O'Riordan

January 19, 2016

News Industry News

Bayer Expands Finerenone Clinical Development Program with Three Phase III Studies for Finerenone in Patients with Diabetic Kidney Disease and Patients with Chronic Heart Failure

August 31, 2015

News Industry News

Novartis' new heart failure medicine LCZ696 approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization; now called Entresto™ (sacubitril-valsartan)

July 07, 2015

News Daily News

Many Patients Referred for Renal Denervation Improve with Medication Adjustment

May 12, 2014

News Daily News

Mortality Benefit with ACE Inhibitors in Nonobstructive CAD

L.A. McKeown

March 20, 2014

News Conference News AHA 2013

Long-term Outcomes with Renal Denervation Show Sustained Benefit

Yael L. Maxwell

November 16, 2013

News Conference News ESC 2013

AQUARIUS: Aliskiren Fails Primary Endpoint But Surprises with MACE Reduction

Caitlin E. Cox

September 04, 2013

News Daily News

Meta-analysis: Heart Failure Worsens Short-term Prognosis of NSTE-ACS Patients

June 28, 2013

News Conference News TCT 2012

Experts Discuss Future of Renal Denervation

October 25, 2012

News Daily News

Renal Denervation Bonus: Improving LV Function

March 05, 2012

News Daily News

Angiotensin Blocker Preserves Endothelial Function Better Than Calcium Antagonist

Jason Kahn

March 05, 2012

Advertisement

Blood Pressures Measured at Home Better Predict CAD Events Than Do Clinic Readings

Comparative Analysis Suggests ACE Inhibitors Equivalent to ARBs in Patients Without Heart Failure

Bayer Expands Finerenone Clinical Development Program with Three Phase III Studies for Finerenone in Patients with Diabetic Kidney Disease and Patients with Chronic Heart Failure

Novartis' new heart failure medicine LCZ696 approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization; now called Entresto™ (sacubitril-valsartan)

Many Patients Referred for Renal Denervation Improve with Medication Adjustment

Mortality Benefit with ACE Inhibitors in Nonobstructive CAD

Long-term Outcomes with Renal Denervation Show Sustained Benefit

AQUARIUS: Aliskiren Fails Primary Endpoint But Surprises with MACE Reduction

Meta-analysis: Heart Failure Worsens Short-term Prognosis of NSTE-ACS Patients

Experts Discuss Future of Renal Denervation

Renal Denervation Bonus: Improving LV Function

Angiotensin Blocker Preserves Endothelial Function Better Than Calcium Antagonist

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content